Molecular Therapeutics

分子治疗-摘要 分子治疗学（MT）项目的使命是将实验室发现转化为临床， 促进基础和临床科学家之间的合作，以改善癌症患者的生活， 确定新的分子、靶点和治疗癌症的策略。这个高度互动的项目包括 来自韦恩州立大学和Karmanos癌症研究所11个系和4所学校的50名成员 (KCI)网络和3，031，514美元的同行评审，癌症相关资金，其中971，206美元来自NCI。 此外，行业赞助的临床试验资金为29，599，781美元。计划成员资格包括一个交叉 KCI中的实验室和临床研究者部分，他们通过计划活动进行互动， 在研究赠款和制药商发起的临床试验方面进行合作。MT计划的科学主题 目的是：1）识别和验证用于选择性肿瘤靶向的新疗法、靶点和途径; 2）识别 肿瘤反应的细胞/分子决定因素和生物标志物;以及3）验证新药剂的有效性 在介入治疗试验中。MT计划专注于治疗癌症的新方法，包括 药物发现，以机制为基础的努力，强调新的肿瘤靶向和 标准试剂和关键信号通路，所有这些都是为了临床转化。MT的利益 成员包括肿瘤代谢、核转运蛋白、转录靶点和信号通路， 扩展到治疗对肿瘤浸润免疫细胞的影响。生物标志物研究包括药代动力学 和药效学、细胞和分子生物标志物以及预测 对治疗的反应和/或导致可行的治疗。一个特别的重点是生物标志物相关 非裔美国人和白色患者之间的癌症差异作为治疗目标， 治疗试验MT计划的研究来自我们的国内/国际公认的临床试验 KCI的项目，该项目采用肿瘤分析（包括基因组分析）来促进I期研究的招募 和早期II期试验，并确定最有可能对特定治疗产生反应的患者。II期临床 试验从基本的实验室发现中得出，最终在制药商发起的临床试验中达到高潮。MT成员领导 III期试验，通常与多中心团队和合作团体合作。MT计划成员学习所有 主要癌症类型，包括KCI集水区发病率高的癌症。这些举措 帮助确定我们的集水区的癌症健康差异，确定肿瘤生物学的种族差异， 导致大量非裔美国人参与临床试验。MT计划的首要目标 开展和提供以患者为中心的癌症研究和治疗，使流域内的患者受益 区MT计划成员与MI、TBM和PSDR计划成员广泛合作， KCI在2015年12月至2019年11月期间发表的935篇手稿中，34%和32%是内部的。 和跨方案，62%是多机构合作。

MOLECULAR THERAPEUTICS – ABSTRACT The mission of the Molecular Therapeutics (MT) Program is to translate laboratory findings to the clinic and to facilitate collaborations between basic and clinical scientists, to improve the lives of patients with cancer by identifying new molecules, targets, and strategies for treating cancer. This highly interactive Program includes 50 members from 11 departments and 4 schools at Wayne State University and the Karmanos Cancer Institute (KCI) Network and $3,031,514 in peer reviewed, cancer-related funding, of which $971,206 is from the NCI. Additionally, industry-sponsored clinical trial funding is $29,599,781. Program membership includes a cross section of laboratory-based and clinical investigators in the KCI who interact through programmatic activities and collaborate on research grants and investigator-initiated clinical trials. The scientific themes of the MT Program are to: 1) identify and validate novel therapeutics, targets and pathways for selective tumor targeting; 2) identify cellular/molecular determinants and biomarkers of tumor response; and 3) validate effectiveness of new agents in interventional treatment trials. The MT Program focuses on new approaches for treating cancer, ranging from drug discovery to mechanism-based efforts emphasizing mechanisms-of-action of novel tumor-targeted and standard agents and critical signaling pathways, all with the goal of clinical translation. The interests of MT members include tumor metabolism, nuclear transporters, transcriptional targets, and signaling pathways, and extend to the impact of therapy on tumor-infiltrating immune cells. Biomarker research includes pharmacokinetics and pharmacodynamics, cellular and molecular biomarkers and molecular/genetic profiles predictive of responses to therapy and/or that lead to actionable therapies. A particular emphasis is on biomarkers relevant to cancer disparities between African American and white patients as treatment targets and for personalized treatment trials. Research in the MT Program draws from our nationally/internationally recognized clinical trials program at KCI, which employs tumor profiling (including genomic profiling) to facilitate enrollment on phase I and early phase II trials and to identify patients most likely to respond to particular treatments. Phase II clinical trials draw from basic laboratory findings, culminating in investigator-initiated clinical trials. MT members lead phase III trials, often working with multi-center teams and cooperative groups. MT Program members study all major cancer types including those that occur at high incidence in the KCI catchment area. These initiatives have helped define cancer health disparities in our catchment area, identify racial differences in tumor biology, and led to enrollment of large numbers of African Americans in clinical trials. The overriding goal of the MT Program is to conduct and deliver patient-centered cancer research and treatment to benefit patients in the catchment area. MT Program members extensively collaborate with members of the MI, TBM, and PSDR Programs at KCI. Of the 935 manuscripts published between December 2015 and November 2019, 34% and 32% were intra- and inter-programmatic, respectively, and 62% were multi-institutional collaborations.